Expression of Translocator Protein and [18F]-GE180 Ligand Uptake in Multiple Sclerosis Animal Models
Authors:
- Anne NackANAnne Nack
- Matthias BrendelMBMatthias Brendel
- Julia NedelcuJNJulia Nedelcu
- Markus DaerrMDMarkus Daerr
- Stella NyamoyaSNStella Nyamoya
- Cordian BeyerCordian Beyer
- Carola FockeCFCarola Focke
- Chloé HoornaertCHChloé Hoornaert
- Peter PonsaertsPPPeter Ponsaerts
- Christoph SchmitzCSChristoph Schmitz
- Peter BartensteinPBPeter Bartenstein
Open Access
Abstract
Positron emission tomography (PET) ligands targeting the translocator protein (TSPO) represent promising tools to visualize neuroinflammation in multiple sclerosis (MS). Although it is known that TSPO is expressed in the outer mitochondria membrane, its cellular localization in the central nervous system under physiological and pathological conditions is not entirely clear. The purpose of this study was to assess the feasibility of utilizing PET imaging with the TSPO tracer, [18F]-GE180, to detect histopathological changes during experimental demyelination, and to determine which cell types express TSPO. C57BL/6 mice were fed with cuprizone for up to 5 weeks to induce demyelination. Groups of mice were investigated by [18F]-GE180 PET imaging at week 5. Recruitment of peripheral immune cells was triggered by combining cuprizone intoxication with MOG35–55 immunization (i.e., Cup/EAE). Immunofluorescence double-labelling and transgene mice were used to determine which cell types express TSPO. [18F]-GE180-PET reliably detected the cuprizone-induced pathology in various white and grey matter regions, including the corpus callosum, cortex, hippocampus, thalamus and caudoputamen. Cuprizone-induced demyelination was paralleled by an increase in TSPO expression, glia activation and axonal injury. Most of the microglia and around one-third of the astrocytes expressed TSPO. TSPO expression induction was more severe in the white matter corpus callosum compared to the grey matter cortex. Although mitochondria accumulate at sites of focal axonal injury, these mitochondria do not express TSPO. In Cup/EAE mice, both microglia and recruited monocytes contribute to the TSPO expressing cell populations. These findings support the notion that TSPO is a valuable marker for the in vivo visualization and quantification of neuropathological changes in the MS brain. The pathological substrate of an increase in TSPO-ligand binding might be diverse including microglia activation, peripheral monocyte recruitment, or astrocytosis, but not axonal injury.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (KI 1469/8-1)
This publication has 80 references indexed in Scilit:
- TSPO regulation in reactive gliotic diseasesJournal of Neuroscience Research, 2018
- Combination of cuprizone and experimental autoimmune encephalomyelitis to study inflammatory brain lesion formation and progressionGlia, 2017
- The development of an automated and GMP compliant FASTlab™ Synthesis of [18F]GE‐180; a radiotracer for imaging translocator protein (TSPO)Journal of Labelled Compounds and Radiopharmaceuticals, 2013
- Myelin debris regulates inflammatory responses in an experimental demyelination animal model and multiple sclerosis lesionsGlia, 2012
- Caudate nuclei volume, diffusion tensor metrics, and T2 relaxation in healthy adults and relapsing‐remitting multiple sclerosis patients: Implications for understanding gray matter degenerationJournal of Magnetic Resonance Imaging, 2008
- Visualising microglial activation in vivoGlia, 2002
- GFAP promoter-controlled EGFP-expressing transgenic mice: A tool to visualize astrocytes and astrogliosis in living brain tissueGlia, 2000
- PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitisJournal of Neuroscience Research, 1997
- Phagocytic activity of macrophages and microglial cells during the course of acute and chronic relapsing experimental autoimmune encephalomyelitisJournal of Neuroscience Research, 1994
- PET Imaging of human gliomas with ligands for the peripheral benzodiazepine binding siteAnnals of Neurology, 1989